Overview

Induction FLOT With CROSS CRT for Esophageal Cancer

Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This study evaluates a novel regimen of induction chemotherapy using a combination of docetaxel, oxaliplatin, and leucovorin, with short term infusional 5-FU (FLOT), given prior to chemoradiotherapy with concurrent carboplatin and paclitaxel, as neoadjuvant therapy prior to definitive surgical resection for patients with adenocarcinoma of the esophagus or gastroesophageal junction
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Cancer Institute (NCI)